IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CENTER

IN	THE UNI	TED STATES PATEN	T AND TRADEMARK OFFICE CENT
In re Applica	tion of:	Bertram Weiss et al.	MAR 0 9 200
Serial No.: 09			Group Art Unit: 1653
Filed: May 31	1,2001		Examiner: Robert B. Mondesi
		AS A TARGET FOR BU DISEASE	RTH CONTROL AND TREATMENT OF
INFORMAT	TION DIS	CLOSURE STATEME	NT UNDER 37 CFR §§ 1.56, 1.97 and 1.98
Commissione P.O. Box 145 Alexandria, V Sir: This is	0 /A 22313- nformation	1450	nade in accordance with 37 C.F.R. §§ 1.56, 1.97
Timing and F			
Under	· 37 C.F.R.	§ 1.97(b), no fee or stanent is filed:	tement is required for filing this information
	within the		late of a national application other than a CPA
	within th		l filing date of the national phase of a PCT
	before the RCE).	e mailing of a first substa	ntive office action (including after filing of an

specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR

Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods

a notice of allowance under 37 C.F.R. § 1.311; and

 \boxtimes

		is accompanied by:				
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR			
		\boxtimes	a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).			
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:			
			a final action under 37 C.F.R. § 1.113;			
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR			
-			a notice of allowance under 37 C.F.R. § 1.311;			
	AND i	is filed	on or before payment of the issue fee; AND is accompanied by:			
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).			
Staten	nents Ui	nder 37	C.F.R. 1.97(e)			
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or			
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.			
Cited 1	Materia	<u>ls</u>				
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).				
		Copies of materials listed and attached were cited in an international search report dated October 21, 2003.				
		Copies	of the materials listed are attached (except for the foregoing).			

Non-E	<u>ngiish i</u>	Language References				
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).				
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:				
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document 				
		A = document defining the general state of the art O = non-written disclosure				
		P = intercalated document				
		T = document cited to understand the theory or principle underlying the invention				
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date				
		D = cited in the application				
		L = cited for another reason				
		& = publication of member of same patent family				
		Translation of other relevant information on foreign search report				
Other	Informa	ation				
Pavme	nt of Fe	ees Due (If Any):				
		ck for \$180.00 covering the fee identified above is attached.				
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.				

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Richard M. Lebovitz, Reg. No. 37,067

Attorney Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1810

Date: February 26, 2004

RML:jmj



MAR 0 9 2004

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	09/867,753	
INFO	RMATION	DIS	CLOSURE	Filing Date	May 31, 2001	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Bertram Weiss et al.	
(use as many sheets as necessary)				Group Art Unit	1653	
				Examiner Name	Robert B. Mondesi	
Sheet	1	of	1	Attorney Docket Number	SCH-1810	

Sheet	1	l of	11	Attorney Docket Number	SCH-1810		
		*-	NON PATENT	LITERATURE DOCUMEN	TS		
Examiner Initials *	Cite No.1	Include name o journal, serial, syr	of the author (in CAPITAL LE	ETTERS), tille of the article (when app e, page(s), volume-issue number(s), p	propriate), title of the item (book, magazine, ublisher, city and/or country where published.	T 2	
		The Pem, Homeobox Gene, Androgen-Dependent And -Independent Promoters And Tissue-Specific Alternative RNA Splicing, March 22, 1996, Sourindra Maiti et al.					
W-17		Androgen regulation of the Pem Homeodomain gene in mice and rat Sertoli and epididymal cells, The University of Texas M.D. Anderson Cancer Center, Sutton KA et al.					
		XP-0022586	615 - December 21,	1999, Leonard, S. et al.			
		XP-0022586	316 - December 16,	1999, NCI-CGAP			
				et al.: "The Pem homeoboocalization, and expression	x gene: Rapid evolution of the in reproductive tissue"		
			614 - Geserick Chris -like class of homeol		ogen-regulated human member		
			ayne et al "Two no ectively expressed ir	vel human X-linked homeob n the testis"	pox genes, hPEPP1 and		
			W-14				
	·*************************************						
	•••						

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.